Miniatura

Fitxers

fendo-14-1269787.pdf (1.37 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-10-31

Llicència de publicació

cc by (c) Marques Pamies, Montserrat et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/205747

Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3389/fendo.2023.1269787

Resum

Introduction: We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2) .Methods: A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs' response. Those patients whose IGF1 decreased to <3SDS from normal value were considered responders and those whose IGF1 was >= 3SDS, were considered non-responders. The 2 hours GH value (GH2h) after s.c. administration of 100 mcg of octreotide was used to define predictive cutoffs. E-cadherin and SSTR2 immunostaining in somatotropinoma tissue were investigated in 24/47 and 18/47 patients, respectively.Results: In all, 30 patients were responders and 17 were non-responders. GH(2h) was 0.68 (0.25-1.98) ng/mL in responders vs 2.35 (1.59-9.37) ng/mL in non-responders (p<0.001). GH(2h) = 1.4ng/mL showed the highest ability to identify responders (accuracy of 81%, sensitivity of 73.3%, and specificity of 94.1%). GH(2h) = 4.3ng/mL was the best cutoff for non-response prediction (accuracy of 74%, sensitivity of 35.3%, and specificity of 96.7%). Patients with E-cadherin-positive tumors showed a lower GH(2h) than those with E-cadherin-negative tumors [0.9 (0.3-2.1) vs 3.3 (1.5-12.1) ng/mL; p<0.01], and patients with positive E-cadherin presented a higher score of SSTR2 (7.5 +/- 4.2 vs 3.3 +/- 2.1; p=0.01).Conclusion: The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in patients with acromegaly.

Matèries

Acromegàlia, Somatostatina

Matèries (anglès)

Acromegaly, Somatostatin

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

MARQUES PAMIES, Montserrat, GIL, Joan, VALASSI, Elena, HERNÁNDEZ, Marta, BIAGETTI, Betina, GIMÉNEZ PALOP, Olga, MARTÍNEZ, Silvia, CARRATO, Cristina, PONS, Laura, VILLAR TAIBO, Rocío, ARAUJO CASTRO, Marta, BLANCO, Concepción, SIMÓN, Inmaculada, SIMÓ SERVAT, Andreu, XIFRA, Gemma, VÁZQUEZ, Federico, PAVÓN, Isabel, GARCÍA CENTENO, Rogelio, ZAVALA, Roxana, HANZU, Felicia a., MORA, Mireia, AULINAS, Anna, VILARRASA, Nuria, LIBRIZZI, Soledad, CALATAYUD, María, DE MIGUEL, Paz, ÁLVAREZ ESCOLÁ, Cristina, PICÓ, Antonio, SAMPEDRO, Miguel, SALINAS, Isabel, FAJARDO MONTAÑANA, Carmen, CÁMARA, Rosa, BERNABÉU, Ignacio, JORDÀ, Mireia, WEBB, Susan m., MARAZUELA, Mónica, PUIG DOMINGO, Manuel. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly. _Frontiers in Endocrinology_. 2023. Vol. 14. [consulta: 14 de gener de 2026]. ISSN: 1664-2392. [Disponible a: https://hdl.handle.net/2445/205747]

Exportar metadades

JSON - METS

Compartir registre